Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction

DOI Web Site 被引用文献3件
  • Marc A. Pfeffer
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Sally C. Greaves
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • J. Malcolm O. Arnold
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Robert J. Glynn
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Frances S. LaMotte
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Richard T. Lee
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Francis J. Menapace
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Elliot Rapaport
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Paul M. Ridker
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Jean-Lucien Rouleau
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Scott D. Solomon
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.
  • Charles H. Hennekens
    From the Brigham and Women’s Hospital (M.A.P., S.C.G., R.J.G., F.S.L., R.T.L., P.M.R., S.D.S., C.H.H.), Boston, Mass; Victoria Hospital (J.M.O.A.), London, Ontario, Canada; Geisinger Medical Center (F.J.M.), Danville, Pa; University of California, San Francisco (E.R.); and Montréal Heart Institute (J.L.R)., Montréal, Québec, Canada.

書誌事項

タイトル別名
  • The Healing and Early Afterload Reducing Therapy Trial

説明

<jats:p> <jats:italic>Background</jats:italic> Although ACE inhibitor therapy has been shown to reduce mortality in patients with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not been determined. </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> In a double-blind trial of 352 patients with anterior MI, we compared the safety and effectiveness of early (day 1) versus delayed (day 14) initiation of the ACE inhibitor ramipril (10 mg) on echocardiographic measures of left ventricular (LV) area and ejection fraction (EF). An early, low-dose ramipril (0.625 mg) arm was also evaluated. Clinical events did not differ. During the first 14 days, the risk of manifesting a systolic arterial pressure of ≤90 mm Hg was increased in both ramipril groups. LVEF increased in all groups during this period, but the early, full-dose ramipril group had the greatest improvement in EF (increase: full, 4.9±10.0; low, 3.9±8.2%; delayed, 2.4±8.8%; <jats:italic>P</jats:italic> for trend <.05) and was the only group that did not demonstrate a significant increase in LV diastolic area. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> The results of the present study demonstrated that in patients with anterior MI, the early use of ramipril (titrated to 10 mg) attenuated LV remodeling and was associated with a prompter recovery of LVEF. The use of low-dose regimen did not prevent hypotension and had only intermediate benefits on LV size and function. The more favorable effects on LV topography of the early use of full-dose ramipril support the results of the major clinical trials, which have demonstrated an early survival benefit of ACE inhibition. </jats:p>

収録刊行物

  • Circulation

    Circulation 95 (12), 2643-2651, 1997-06-17

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ